论文部分内容阅读
[目的]探讨ⅢA期非小细胞肺癌患者新辅助化疗后p53、MRP蛋白表达水平与患者预后的相关性。[方法]检测73例经新辅助化疗的ⅢA期非小细胞肺癌患者术后标本p53、MRP蛋白表达水平。采用Kaplan-Meier法和Log-Rank检验分析生存率,采用Cox模型作多因素分析。[结果]新辅助化疗73例患者完全缓解(CR)4例、部分缓解(PR)36例,总有效率为54.79%。73例患者术后3年生存率为35.62%,p53、MRP蛋白表达阴性者术后3年生存率均高于阳性者(P<0.05)。Cox多因素分析显示p53、MRP蛋白表达水平、淋巴结转移、肿瘤分化程度、化疗疗效与患者预后呈显著性相关。[结论]p53、MRP蛋白的表达水平与新辅助化疗患者的预后相关,可以预测化疗疗效,指导临床化疗。
[Objective] To investigate the correlation between p53, MRP protein expression and prognosis in patients with stage ⅢA non-small cell lung cancer after neoadjuvant chemotherapy. [Method] To detect the expression of p53 and MRP protein in 73 patients with stage Ⅲ A non-small cell lung cancer after neoadjuvant chemotherapy. Survival rates were analyzed using Kaplan-Meier method and Log-Rank test, and Cox model was used for multivariate analysis. [Results] In the 73 cases of neoadjuvant chemotherapy, there were 4 cases of complete remission (CR), 36 cases of partial remission (PR), the total effective rate was 54.79%. The 3-year survival rate was 35.62% in 73 patients. The 3-year survival rates of patients with negative p53 and MRP protein expression were significantly higher than those with positive expression (P <0.05). Cox multivariate analysis showed that p53, MRP protein expression, lymph node metastasis, tumor differentiation, chemotherapy and prognosis were significantly correlated. [Conclusion] The expression of p53 and MRP protein is correlated with the prognosis of patients with neoadjuvant chemotherapy, which can predict the effect of chemotherapy and guide the clinical chemotherapy.